Institut National De La Sante Et De La Recherche Medicale

Oregon Health & Science University

Aventis Pasteur Limited

Other

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Université Paris Descartes

Smithkline Beecham Corporation

Assistance Publique - Hopitaux De Paris (aphp)

Assistance Publique-hopitaux De Paris

Xavier Nassif

Jean-Louis Ruelle

Annabelle Bouchardon

Bachra Rokbi

Stefano Marullo

Colin Tinsley

Fred L Heffron

Igor Stojiljkovic

Vivian Hwa

Magdalene So

Luc Aujame

Geneviève Renauld-Mongenie

Agnès Perrin

Sandrine Bourdoulous

Mark Achtman

Agn&egrave;s Perrin

Jean-Luc Beretti

Silke Klee

Etienne Carbonnelle

Petra Merker

Agnès Ferroni

Marie Elisabeth Bougnoux

Genevi&egrave;ve Renauld-Mongenie

Nicolas Degand

Olivier Join-Lambert

Alexandre Alanio

Mathieu Coureuil

Brunhilde Dauphin

Agnes Ferroni

Carla Vinals

The present invention concerns the use of an inhibitor of an interaction between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147.

[object Object]

The DNA of the invention are characterized in that they concern the whole or part of genes, with their reading frame, to be found in, but not in, or inexcept the genes involved in the biosynthesis of the polysaccharide capsule, frp A, frp C, opc, por A, rotamase the sequence IC1106, IgA protease, pilline, pilC, transferrin binding proteins and opacity proteins. The invention also concerns the polypeptides corresponding to these DNA and the antibodies directed against these polypeptides. It is applicable in the prevention and the detection of meningococcus induced infections and meningitis.

The invention concerns nucleic acids coding for polypeptides specific of thegenus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.

The invention relates to a method for identifying a strain isolated from a clinical sample, at the species and/or subspecies level, using MALDI-TOF-MS analysis comprising a step of classifying the germ in a group before performing the MALDI-TOF-MS analysis.

Means for identifying a strain isolated from a clinical sample at the species and/or subspecies level

The invention provides novel(Nm) polypeptides and polynucleotides which cover the Nm genetic diversity, and which correspond to polypeptide of Nm outer membrane and/or periplasma, and to methods for producing such Nm compounds. Also provided are anti-Nm infection, and particularly diagnostic. prophylactic and therapeutic uses thereof.

The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in, but not in, or inexcept the genes involved in the biosynthesis of the polysaccharide capsule, frp A, frp C, opc, por A, rotamase the sequence IC1106, IgA protease, pilline, pilC, transferrin binding proteins and opacity proteins. The invention also concerns the polypeptides corresponding to these DNA and the antibodies directed against these polypeptides. It is applicable in the prevention and the detection of meningococcus induced infections and meningitis.

DNAs and proteins or peptides specific to bacteria of the species Neisseria meningitidis, processes for obtaining them and their biological uses

The present invention relates to novel bacterial hemoglobin receptor proteins and genes that encode such proteins. The invention is directed toward the isolation, characterization, diagnostic and therapeutic use of bacterial hemoglobin receptor proteins, nucleic acid encoding such proteins, recombinant expression constructs comprising such nucleic acids and cells transformed therewith, and antibodies and epitopes of such hemoglobin receptor proteins. The invention relates particularly to hemoglobin receptor proteins and genes encoding such proteins fromspecies, especiallyand serotypes thereof, and. Methods for the diagnostic and therapeutic use of the proteins, epitopes, antibodies and nucleic acids of the invention are also provided, including the use of the proteins, epitopes, antibodies and nucleic acids of the invention for the production of vaccines effectinve in providing immunization of a human against infection by pathogenic bacteria ofspecies.

Bacterial hemoglobin receptor genes

The invention concerns nucleic acids coding for polypeptides specific of the genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.

Nucleic acids and polypeptides specific of the neisseria genus pathogenic strains

The present invention relates to novel bacterial hemoglobin receptor proteins and genes that encode such proteins. The invention is directed toward the isolation, characterization, diagnostic and therapeutic use of bacterial hemoglobin receptor proteins, nucleic acids encoding such proteins, recombinant expression constructs comprising such nucleic acids and cells transformed therewith, and antibodies and epitopes of such hemoglobin receptor proteins. The invention relates particularly to hemoglobin receptor proteins and genes encoding such proteins from Neisseria species, especially,and serotypes thereof, and,. Methods for the diagnostic and therapeutic use of the proteins, epitopes, antibodies and nucleic acids of the invention are also provided, including the use of proteins, epitopes, antibodies and nucleic acids of the invention for the production of vaccines effective in providing immunization of human against infection by pathogenic bacteria of Neisseria species.

Hemoglobin receptors from neisseriae

The present invention relates to a novel bacterial hemoglobin receptor protein and genes that encode such a protein. The invention is directed toward the isolation, characterization, diagnostic and therapeutic use of a bacterial hemoglobin receptor protein, nucleic acid encoding such a protein, recombinant expression constructs comprising such nucleic acids and cells transformed therewith, and antibodies and epitopes of such hemoglobin receptor proteins. The invention relates particularly to hemoglobin receptor proteins and genes encoding such proteins from Neisseria species, especially N. meningitidis. Methods for the diagnostic and therapeutic use of the proteins, epitopes, antibodies and nucleic acids of the invention are also provided, including the use of the proteins, epitopes, antibodies and nucleic acids of the invention for the production of vaccines effectinve in providing immunization of a human against infection by pathogenic bacteria of Neisseria species.

Bacterial hemoglobin receptor gene

The present invention relates to novel bacterial hemoglobin receptor proteins and genes that encode such proteins. The invention is directed toward the isolation, characterization, diagnostic and therapeutic use of bacterial hemoglobin receptor proteins, nucleic acid encoding such proteins, recombinant expression constructs comprising such nucleic acids and cells transformed therewith, and antibodies and epitopes of such hemoglobin receptor proteins. The invention relates particularly to hemoglobin receptor proteins and genes encoding such proteins from Neisseria species, especially N. meningitidis and serotypes thereof, and N. gonorrhoeae. Methods for the diagnostic and therapeutic use of the proteins, epitopes, antibodies and nucleic acids of the invention are also provided, including the use of the proteins, epitopes, antibodies and nucleic acids of the invention for the production of vaccines effective in providing immunization of a human against infection by pathogenic bacteria of Neisseria species.

The present invention relates to a novel bacterial hemoglobin receptor protein and genes that encode such a protein. The invention is directed toward the isolation, characterization, diagnostic and therapeutic use of a bacterial hemoglobin receptor protein, nucleic acid encoding such a protein, recombinant expression constructs comprising such nucleic acids and cells transformed therewith, and antibodies and epitopes of such hemoglobin receptor proteins. The invention relates particularly to hemoglobin receptor proteins and genes encoding such proteins from Neisseria species, especially N. meningitidis. Methods for the diagnostic and therapeutic use of the proteins, epitopes, antibodies and nucleic acids of the invention are also provided, including the use of the proteins, epitopes, antibodies and nucleic acids of the invention for the production of vaccines effective in providing immunization of a human against infection by pathogenic bacteria of Neisseria species.

Growing community of inventors

Paris, France

Xavier Nassif